(S,R,S)-AHPC-C2-PEG3-BCN (CAS 2876198-36-4) is a bifunctional molecule designed for targeted protein degradation research. It integrates a VHL ligand (AHPC) to recruit E3 ubiquitin ligase, a PEG3 linker for flexibility and spacing, and a BCN group for bioorthogonal conjugation.
Key Features:
- VHL Ligand (AHPC): Targets the von Hippel-Lindau (VHL) E3 ubiquitin ligase.
- PEG3 Linker: Provides optimal spacing and flexibility for efficient conjugation.
- BCN Group: Enables bioorthogonal reactions with azides and other strained alkyne systems.
- High Purity: Ensures reproducible results in biochemical research.
Applications:
- PROTAC Development: Facilitates the design of proteolysis-targeting chimeras (PROTACs) for targeted protein degradation.
- Drug Discovery: Supports the exploration of novel therapeutic targets.
- Bioconjugation: Enables precise modification of biomolecules.
- Chemical Biology: Advances studies in protein labeling and degradation pathways.
This molecule is a versatile tool for advancing research in targeted protein degradation and therapeutic development.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
